The growth of Viagra and its influence on the drug landscape presents a complex question for traders. While the initial sales figures were remarkable, the intellectual property has expired, leading to a flood of generic alternatives that are chipping away at earnings. Moreover, the sector is facing difficulties related to aging trends and changing